Deals
Zymeworks Authorizes Up To $200 Million In Buybacks — It Expects To Spend Less
The biotech plans approximately $140 million in purchases through 2028 while funding drug development and selective acquisitions.
Zymeworks (ZYME) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Deals
The biotech plans approximately $140 million in purchases through 2028 while funding drug development and selective acquisitions.
Deals
The higher forecast depends on Roche antitrust clearance, while Theravance acquisition costs pushed selling and administrative expenses higher.
SEC Filings
Zymeworks could collect up to $718 million more in milestones, plus royalties, if the deal clears U.S. antitrust review.